RESUMEN
In recent years,ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC);however,the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients,and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs,such as monoclonal antibody,fibroblast growth factor 19,and sodium-dependent bile acid transporter inhibitor,have limited efficacy data,they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy,the management of PBC patients will enter a new stage.
RESUMEN
Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is the only safe and effective drug for PBC approved by FDA. To date, there is no unified therapeutic regimen for patients with suboptimal response to UDCA. Fibrates are a class of synthesized ligands of peroxisome proliferator-activated receptors, and recent studies have shown that fibrates may have anticholestatic, anti-inflammatory, and antifibrotic effects. The article reviews the application of fibrates in the treatment of PBC and possible mechanisms.